SPARK Oppenheimer summit virtual event **Agenda**

Presentation Time (Eastern Standard Time)	Presentations
11:15 - 11:30 EST ***(08:15 – 08:30 PST)***	***SPARK Program Overview – Introduction*** **Jeewon Kim, PhD, MBA, Associate Director of Business Development, SPARK Translational Research Program, Stanford University** Dr. Kim is a science-trained business developer and her interests include the translation of promising academic discoveries (indication-agnostic) into novel therapeutics and diagnostics and discovery, development of new drugs, biologics, and diagnostics and repurposing existing drugs for novel targets for new clinical indications. She received her PhD from UC Berkeley and post-doctoral training at Stanford, where she was a fellow of NIH tumor biology training grant. She received her MBA from Boston University with high honors. She worked at both large and small companies before coming to SPARK.
11:30 - 12:00 EST ***(08:30 - 09:00 PST)***	***Andreasson Lab*** **Professor Katrin Andreasson, MD, Professor of Neurology & Neurological Sciences** Dr. Andreasson is a neurologist who treats patients with dementia and is also engaged in basic research in neurodegenerative disorders. Dr. Andreasson received her MD at Columbia University and completed her residency in Neurology at Johns Hopkins. She did postdoctoral training in the Johns Hopkins Department of Neuroscience. The objectives of her laboratory research are to identify specific inflammatory pathways that may be targeted to prevent and treat neurodegenerative disorders such as Parkinson's disease and Alzheimer's disease.
12:00 - 12:30 EST ***(09:00 – 09:30 PST)***	***Turn Bio*** **Professor Vittorio Sebastiano, PhD, Assoc. Prof. (Research) of Obstetrics and Gynecology (Reproductive, Perinatal & Stem Cell Biology Research), Co-Founder and Head of Research at Turn Bio** As a Professor at Stanford University Medical School, Dr. Sebastiano led development of the unique mRNA-based ERA™ (Epigenetic Reprogramming of Aging) platform Turn Bio uses to develop novel mRNA medicines to cure untreatable, age-related conditions. Dr. Sebastiano has served as chairman of Turn Bio's Scientific Advisory Board since he co-founded the company in 2018. His Stanford University lab pioneered the development of a new paradigm for treating aging and age-related diseases. He also led the team that first confirmed human cells can be reprogrammed using Turn Bio's ERA platform.
12:30 - 13:00 EST ***(09:30 – 10:00 PST)***	***BioAge Labs*** **Kristen Fortney, PhD, Co-Founder, CEO of BioAge** Kristen has served as CEO and board member of BioAge since co-founding the company in 2015. Kristen is a scientifically trained biotech executive with extensive experience building discovery platforms, building teams, fundraising, and scientific & clinical strategy.

	She serves as an advisor to multiple biotechnology companies. Kristen's scientific background is in aging biology, genetics, and bioinformatics. She did her PhD in Medical Biophysics at the University of Toronto and post-doc at Stanford University where she was a fellow of the American Federation for Aging Research.
13:00 - 13:30 EST ***(10:00 - 10:30 PST)***	***Svensson Lab*** **Professor Katrin Svensson, PhD, Asst. Prof. of Pathology, Affinity Group Leader, Stanford Diabetes Research Center** Dr. Svensson is Assistant Professor of Pathology at Stanford University and one of the Affinity group leaders at the Stanford Diabetes Research Center (SDRC). She received her PhD in 2012 from Lund University in Sweden and completed her postdoctoral studies at Harvard Medical School and the Dana-Farber Cancer Institute in Boston. She is an Associate Editor at Endocrine Reviews, and is on the Advisory Board for STAR Protocols.
13:30 - 14:00 EST ***(10:30 - 11:00 PST)***	***Long Lab*** **Professor Jonathan Long, PhD, Assoc. Prof. of Pathology and ChEM-H Institute Scholar** Dr. Long received his BA from Columbia University in NYC. He completed his PhD at The Scripps Research Institute in the laboratory of Benjamin F. Cravatt and moved to Boston first as a postdoctoral fellow and then later as Instructor of Cell Biology in the laboratory of Bruce M. Spiegelman at the Dana-Farber Cancer Institute and Harvard Medical School. He investigated the biochemical basis of energy metabolism. Since 2018, Jon has been at Stanford University where his research has been supported by external funding from the ADA, the Ono Pharma Foundation, and the NIH.
14:00 - 14:30 EST ***(11:00 - 11:30 PST)***	***PANEL: Financing, Investing, Partnering*** **Moderator:** Jay Olson, CFA, Senior Research Analyst and Managing Director, Oppenheimer & Co. Inc. **Panelists:** Srini Akkaraju, MD, PhD, Founder and Managing Partner, Samsara BioCapital Chrstiana Bardon, MD, PhD, Co-Managing Partner, MPM BioImpact Maha Katabi, PhD, General Partner, Sofinnova Investments Michael A. Margolis, R.Ph., Managing Director, Head of Healthcare, Head of Healthcare Life Sciences, Investment Banking, Oppenheimer & Co. Inc.
14:30 - 15:00 EST ***(11:30 - 12:00 PST)***	***Closing Remarks***

*** Note all times are in ET.**